Dissolution Profile of Sustained Release Tablet of Diclofenac Sodium Using Metolose 90 SH 4000 Matrix
Article Sidebar
Published:
May 5, 2015
Keywords:
sustained release, diclofenac sodium, metolose 90 SH 4000, dissolusion profile.
Main Article Content
Abstract
Diclofenac sodium (Na-diclofenac) is a non-steroidal anti-inflammatory drug that is commonly used for arthritis patients. However, its short half-life time which is about 1-2 hours causes the drug should be administered repeatedly over a short time interval for oral administration. Therefore, the purpose of this study was to formulate a sustained release tablet of diclofenac sodium with metolose 90 SH 4000 as the matrix. In order to see the influence metolose 90 SH 4000 to the dissolution profile of diclofenac sodium tablet, metolose 90 SH 4000 was added with a ratio of 0% (F0), 5% (F1), 10% (F2), 15% (F3), 25% (F4). The tablets was prepared by wet granulation method. The dissolution results showed the formula F0, F1, F2, and F3 can be reached within 120, 240, 300, and 480 minutes, respectively. Meanwhile, F4 did not reach the dissolution for 480 minutes. According to the USP 26, only F3 qualified the dissolution of sustained release tablet.
Article Details
How to Cite
Agustin, R., & Ratih, H. (2015). Dissolution Profile of Sustained Release Tablet of Diclofenac Sodium Using Metolose 90 SH 4000 Matrix. Jurnal Sains Farmasi & Klinis, 1(2), 176–183. https://doi.org/10.29208/jsfk.2015.1.2.33
Issue
Section
Research Articles
The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.
References
1. Notari, R.E. 1980. Biopharmaceutical Clinical Pharmacokinetics 3rd ed, New York: Marcel Dekker Inc., 152 -157.
2. Hardman, J.G., (Eds). 2001. The Pharmacological Basis of Therapeutics 10 th ed. McGraw-Hill Pub, 688, 709-710.
3. Shin-Etsu Chemical Co, Ltd, 2002. Metolose SR: Sustained Release agent for Matrix system, Tokyo, Japan, 1-2.
4. Bravo A. Silvina, Lamas C. Maria, Salomon J Claudio. 2002. In-Vitro Studies of Diclofenac Sodium Controlled-release from Biopolymeric Hydrophilic Matrices. J Pharm Pharmaceut Sci 5(3):213-219.
5. Lachman, L., 1994. Teori dan Praktek Farmasi Industri, Terjemahan Suyatmi S. dan Aisyah I., jilid 2, Edisi III, UI Press, Jakarta, 643-793.
6. S., Pharmacopeial Convention Inc., The official of standart USP 26/NF 19 U.S., Pharmacopeia.National Formulary, Vol I, Rochville, MD, 2000, 983-984.
7. Direktorat Jenderal POM, Departemen Kesehatan RI, Farmakope Indonesia, ed 3, Departemen Kesehatan RI, Jakarta, 1979, 7, 753-755.
8. Madhusudan Rao, Y., Krishna Veni, J., Jayasagar, G. Formulation and Evaluation of Diclofenac Sodium Using Hydrophilic Matrices, Drug Dev. Ind. Pharm, 2001, 27:759-766.
2. Hardman, J.G., (Eds). 2001. The Pharmacological Basis of Therapeutics 10 th ed. McGraw-Hill Pub, 688, 709-710.
3. Shin-Etsu Chemical Co, Ltd, 2002. Metolose SR: Sustained Release agent for Matrix system, Tokyo, Japan, 1-2.
4. Bravo A. Silvina, Lamas C. Maria, Salomon J Claudio. 2002. In-Vitro Studies of Diclofenac Sodium Controlled-release from Biopolymeric Hydrophilic Matrices. J Pharm Pharmaceut Sci 5(3):213-219.
5. Lachman, L., 1994. Teori dan Praktek Farmasi Industri, Terjemahan Suyatmi S. dan Aisyah I., jilid 2, Edisi III, UI Press, Jakarta, 643-793.
6. S., Pharmacopeial Convention Inc., The official of standart USP 26/NF 19 U.S., Pharmacopeia.National Formulary, Vol I, Rochville, MD, 2000, 983-984.
7. Direktorat Jenderal POM, Departemen Kesehatan RI, Farmakope Indonesia, ed 3, Departemen Kesehatan RI, Jakarta, 1979, 7, 753-755.
8. Madhusudan Rao, Y., Krishna Veni, J., Jayasagar, G. Formulation and Evaluation of Diclofenac Sodium Using Hydrophilic Matrices, Drug Dev. Ind. Pharm, 2001, 27:759-766.